9  -0.05 (-0.55%)		07-26 16:00
Open: 9 High: 9 Volume: 571		Pre. Close: 9.05 Low: 9 Market Cap: 44(M)

Short term
Mid term
Targets	6-month :	10.71	1-year :	11.2
Resists	First :	9.17	Second :	9.59
Pivot price	9.14
Supports	First :	8.5	Second :	7.07
MAs	MA(5) :	9.21	MA(20) :	9.07
	MA(100) :	9.12	MA(250) :	8.97
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	68	D(3) :	76.9
RSI	RSI(14): 46
52-week	High :	10.13	Low :	7.11

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DXR ] has closed above bottom band by 31.0%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	9.02 - 9.07	9.07 - 9.12
Low:	8.85 - 8.91	8.91 - 8.97
Close:	8.89 - 8.99	8.99 - 9.1

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Wed, 24 Jul 2024
Daxor Corporation Awarded New U.S. Defense Health Agency - GlobeNewswire

Wed, 24 Jul 2024
Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer - StockTitan

Thu, 18 Jul 2024
Daxor Corp holds annual meeting, re-elects directors By Investing.com - Investing.com Canada

Thu, 18 Jul 2024
Daxor Corp holds annual meeting, re-elects directors - Investing.com

Wed, 17 Jul 2024
(DXR) Trading Report - Stock Traders Daily

Thu, 11 Jul 2024
Daxor’s BVA-100 blood volume diagnostic expands to three new centers - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	5 (M)
Shares Float	2 (M)
Held by Insiders	56.5 (%)
Held by Institutions	1.7 (%)
Shares Short	9 (K)
Shares Short P.Month	7 (K)

EPS	0.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.07
Profit Margin	171.7 %
Operating Margin	-511.4 %
Return on Assets (ttm)	-1.6 %
Return on Equity (ttm)	0.8 %
Qtrly Rev. Growth	-14.5 %
Gross Profit (p.s.)	0
Sales Per Share	0.03
EBITDA (p.s.)	0
Qtrly Earnings Growth	-57.6 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	64.28
PEG Ratio	0
Price to Book value	1.27
Price to Sales	266.55
Price to Cash Flow	-11.91

Dividend	0.02
Forward Dividend	0
Dividend Yield	0.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.